Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Classical hematology 1

Conditions

Colorectal Neoplasms 24Neoplasms 12Colonic Neoplasms 12Breast Neoplasms 12Prostatic Neoplasms 9Polycythemia Vera 9Venous Thromboembolism 8Multiple Myeloma 8Recurrence 5Rectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Thrombocythemia, Essential 4Ovarian Neoplasms 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Barrett Esophagus 4Precancerous Conditions 3Melanoma 3Esophageal Neoplasms 3Adenomatous Polyps 3Adenoma 3Tobacco Use Disorder 2Thrombosis 2Thromboembolism 2Smoking Cessation 2Sarcoma 2Primary Myelofibrosis 2Neoplastic Cells, Circulating 2Neoplasms by Site 2

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Cyclosporins 14Biopsy 14Alemtuzumab 14thymoglobulin 13venetoclax 11sargramostim 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Myeloproliferative Disorders × Aspirin × Clear all
NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

PharmaEssentia Japan K.K.

Phase 2 Completed
29 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06290765 2025-07-31

PV

PharmaEssentia

Phase 4 Not yet recruiting
70 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

PharmaEssentia Japan K.K.

Phase 3 Completed
21 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT04243122 2024-05-29

AIRPORT-MPN

Ottawa Hospital Research Institute

Phase 2 Completed
44 enrolled
Classical hematologyMyeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡